Gwangju, South Korea

Dong-Yeon Kim

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Dong-Yeon Kim in Melanoma Treatment

Introduction

Dong-Yeon Kim is a prominent inventor based in Gwangju, South Korea. He has made significant contributions to the field of medical technology, particularly in the treatment and diagnosis of melanoma. With a total of 2 patents, his work focuses on developing radioactive compounds that enhance therapeutic and diagnostic capabilities.

Latest Patents

Dong-Yeon Kim's latest patents include two groundbreaking inventions. The first patent is titled "Radioactive compound for treatment of melanoma and use thereof." This invention relates to a radioactive compound that exhibits improved targeting ability for melanoma, offering a pharmaceutical composition that significantly enhances treatment efficacy compared to conventional agents. The second patent, "Radioactive compound for diagnosis of malignant melanoma and use thereof," introduces a novel radioactive compound designed for imaging malignant melanoma. This compound serves as a contrast agent for PET imaging, providing valuable insights for medical professionals.

Career Highlights

Dong-Yeon Kim is affiliated with Chonnam National University, where he continues to advance his research in the field of oncology. His innovative work has positioned him as a key figure in the development of new therapeutic strategies for melanoma.

Collaborations

Some of his notable coworkers include Jung-Joon Min and A-Young Pyo, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Dong-Yeon Kim's contributions to melanoma treatment and diagnosis through his patented innovations highlight the importance of research in improving patient outcomes. His work exemplifies the potential of radioactive compounds in advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…